FDA Finalizes Guidance Documents on Payor Communications and Communications Consistent with LabelingDaniel A. Kracov
The Phase 3, multicenter, open-label extension trial evaluated the long-term safety and efficacy of Dupixent in 365 children with uncontrolled moderate-to-severe asthma who had previously participated in the placebo-controlled VOYAGE trial (the pivotal trial) when they were 6 to 11 years of age....
FDA Releases Draft Guidance on Medical Product Communications Consistent with FDA-Required LabelingDaniel A. Kracov
Daniel A. Kracov
Due to the domain gap, it is difficult for the teacher trained in the source domain to provide adequate guidance to the student in the target domain. In addition, the pseudo-labels generated by the teacher in the target domain usually contain noise, as shown in Figure 1, which includes ...